Cramer's 'Mad Money' Recap: Top Three Speculative Plays for '07

The company has "skilled management" and recently launched a testosterone drug, Oxandrin, that helps promote weight gain after surgery. While those first two traits are good, Cramer said the main reason he considers Savient "exciting" is its phase III drug for gout, Puricase.

Three million to five million Americans suffer from gout, and "they're going to take Puricase if they want anything to work for them," he said.

Cramer said Savient shares could easily double if positive phase III data are released in the third quarter.

No. 2 on Cramer's "sizzling" speculative stocks list is Rite Aid (RAD Quote).

Only 10 analysts cover this stock, and it's not getting support from the Street, he said, adding that he loves it "when a hot stock is unloved."

Cramer believes Rite Aid should be valued higher and urged viewers to get in on the action before the Street figures this one out. He advised people to buy it Monday afternoon.

Not only is the company's deal with Brooks-Eckerd supposed to save Rite Aid $150 million, Cramer said it is the one drugstore that seems to have immunity from the "Wal-Mart (WMT Quote) disease."